CLINICAL STUDY

Type and occurrence of serious complications in patients after mild traumatic brain injury

Sivak S1, Nosal V1, Bittsansky M2, Dluha J1, Dobrota D2, Kurca E1

Clinic of Neurology, Jessenius Medical Faculty, Comenius University, Martin, Slovakia.
egonkurca@gmail.com

ABSTRACT

Traumatic brain injury (TBI) remains a major public health and socio-economic problem, and 70 – 90 % of all TBIs are classified as mild. Mild TBIs and concussions are mostly considered to be non-serious conditions with symptoms subsiding within a few days or weeks. However in some patients, symptoms persist as a post concussion syndrome (PCS). Second-impact syndrome (SIS) is a very rare but usually fatal condition and occurs when repeated brain injuries lead to a catastrophic diffuse brain swelling. There is no scientific evidence on the incidence and risk of SIS. Chronic traumatic encephalopathy (CTE) is a progressive degenerative disease of the brain found in patients with a history of repetitive brain trauma. CTE presents with behavioural, cognitive, and motor symptoms. The literature to date lacks prospective epidemiological studies of the incidence of CTE. In recent medical literature, there is a description of 110 athletes with postmortem diagnosis of CTE (Tab. 1, Ref. 37). Key Words: mild traumatic brain injury; concussion; post concussion syndrome; second-impact syndrome; chronic traumatic encephalopathy.

Mild traumatic brain injury

Traumatic brain injury (TBI) remains a major public health and socio-economic problem. It is estimated that 70–90 % of all TBIs are classified as mild (1). European Federation of Neurological Societies defines mild traumatic brain injury (MTBI) as a head injury with Glasgow Coma Scale (GCS) score of 13–15, and with loss of consciousness (if present) lasting 30 minutes or less (2). Concussion (commotio cerebri) is another traditional term still used in medical terminology in some European countries and it is widely used in sports medicine (3). Concussion is a specific kind of MTBI defined as posttraumatic transient impairment of neurological function that resolves spontaneously and is associated with normal standard structural neuroimaging findings (3). MTBIs and concussions are mostly considered to be non-serious conditions with symptoms subsiding within a few days or weeks. However in some patients, symptoms persist as a post concussion syndrome (PCS) and negatively influence their daily activities.

In our unpublished longitudinal case-control study, postconcussion syndrome was present in 62.5 % of our patients 3–7 months after MTBI. The most common symptoms were poor memory (62.5 %), irritability (54.2 %), headache (54.2 %), drowsiness (50 %), and concentration problems (45.8 %). These findings are consistent with results from other studies. In general population, the prevalence of PCS at 3 months post-injury is between 24 and 84 % (4). It is estimated that 10–15 % of individuals are reported to remain symptomatic one year after concussion (5). These symptoms are not specific for PCS and are associated with other clinical and non-clinical groups including healthy adults (in our
study, 57.1% of controls reported symptoms consistent with PCS), and patients suffering from chronic pain, spinal injury, non-brain trauma, or psychological distress (6).

Whether PCS is experienced after MTBI appears to depend on different neurobiological and psychological factors, including pre-injury depression and anxiety, somatoform disorder, life-stressors, pain, female gender, older age, coping style, cognitive biases such as expectation of symptoms, premature return to full training regime in sport, litigation stress, exaggeration, and malingering (6, 7).

The differential diagnosis of PCS is a multidisciplinary problem and includes headache disorders, cervical injury, visual and vestibular dysfunction, psychiatric disorders such as anxiety, depression or somatization, and malingering. A single psychoeducational session with support and education about the symptoms, expected recovery and gradual resumption of activities prevents or shortens the duration of postconcussion symptoms (8). There are potential benefits of structured and supervised exercise during the post–acute concussion recovery period (6). Lengthy physical inactivity in patients with chronic PCS can lead to prolonged recovery (9). Referral to various specialists should be made according to chronic somatic symptoms as well as mood, cognition, and sleep impairment. Psychotherapy, cognitive–behavioural therapy, education, cognitive training, physiotherapy, or vestibular rehabilitation may aid recovery. For refractory PCS, symptomatic pharmacologic treatment can be helpful (e.g. SSRI, analgesics; hypnotics) (10).

**Second-impact syndrome**

Second-impact syndrome (SIS) is a very rare condition and occurs when an athlete sustains an initial mild head injury, then suffers a second head injury before the symptoms associated with the first impact disappear. After the second impact, the athlete’s condition quickly deteriorates and is often fatal (11). Most of those who survive are severely disabled (12). It was first described in 1973 by Richard Schneider in two athletes and the term second-impact syndrome was coined in 1984 by Saunders and Harbaugh. SIS was described in young athletes, predominantly males (90%) at age of 10 to 24 (mean 17.9 years). Among afflicted athletes were American football players (71%), boxers (14%), and occasionally martial artists, skiers, and ice-hockey players (13, 14). It is assumed, that SIS is caused by catastrophic cerebral oedema resulting from post–traumatic loss of cerebral blood-flow autoregulation combined with stress–induced catecholamine release with high blood pressure (15). Apart from diffuse cerebral oedema, a thin acute subdural hematoma has been described in some cases (16).

Typically, the athlete reports postconcussion symptoms after the first mild traumatic brain injury, such as headache, balance problems, attention and memory problems. Before these symptoms are fully cleared, which may take days or weeks (0–32 days), the patient suffers a second head injury. Cantu and Gean stated that the second injury may be remarkably minor or it can be only a blow to the chest that indirectly leads to transmission of impulsive force to the head and brain. The athlete may appear stunned after the injury, but usually does not experience loss of consciousness. Within several seconds or minutes, the athlete suddenly falls to the ground, is semicomatose or comatose with dilated pupils, and develops respiratory failure. Clinical deterioration occurs more rapidly than usually seen in cases of epidural hematoma (16).

The patient needs cardiopulmonar resuscitation and fast transport to emergency department. Computed tomography (CT) is the initial examination of choice and when intracranial hypertension is detected, neurosurgical intervention and oedema treatment are indicated (16).

This very rare condition still remains controversial. There is no scientific evidence on the incidence and risk of SIS, other than reported case-series from North America. It is not clear whether the initial concussion increases the risk for cerebral swelling after the second injury. It has been suggested that SIS and malignant cerebral oedema after one MTBI could be manifestations of the same pathology (13, 17, 18, 19). In the only systematic review of this topic, a total of 17 cases of reported SIS were identified in the world literature. Of these, only five cases actually suffered a repeated injury (20). Despite these controversies, all return-to-play guidelines recommend that athletes must not return to competition until all concussion symptoms are absent, both at rest and during exercise (3).

**Chronic traumatic encephalopathy**

It has long been known that multiple MTBIs result in late-time dementia. This was initially recognized by American pathologist Dr. Harrison S. Martland in 1928, who described a spectrum of persistent motor and neuropsychiatric symptoms in former professional boxers (21, 22). He coined this syndrome punch-drunk syndrome due to the early signs resembling intoxication, such as dominant unsteadiness, slowed-down movements, and mental confusion. Since 1928, further case reports and series of boxers have been described in medical literature, indicating that repetitive brain injuries can induce chronic and potentially progressive neuropsychiatric symptoms on a neuropathological basis (23). The syndrome was termed with several names such as traumatic encephalopathy of professional pugilists (24), dementia pugilistica (25), chronic progressive traumatic encephalopathy of boxers (26), and chronic traumatic encephalopathy (CTE) (27). The first detailed neuropathological findings of a patient with CTE were described by Brandenburg and Hallervorden in 1954 and later in a group of 15 boxers by Corsellis (28). In 2005, Omal et al described for the first time a case report of an American football player with progressive neuropsychiatric disorder with neuropathological findings similar to those found in boxers with punch-drunk syndrome (29). The understanding that the disorder was not restricted to boxing (pugilism), the broader term of chronic traumatic encephalopathy (CTE) has began to be favoured. CTE has been described in several sports such as American football, ice hockey, wrestling (30), and rugby (13), but also in non-sport cases such as war veterans (31), epilepsy, physical violence (32), self-injury (33), and alcoholics with history of repeated falls (34). At the moment, there is a cohort of 110 athletes with postmortem diagnosis of CTE (23).
Clinical diagnosis of CTE can be problematic as the development of chronic progressive symptoms manifest typically after a period of latency (mostly several years) after the last brain injury. Jordan has proposed clinical criteria for CTE, which have not been validated yet (35). The definitive diagnosis requires neurological signs consistent with CTE and pathological confirmation. The probable diagnosis needs two or more of the following conditions: 1) cognitive and/or behavioral impairment; 2) cerebellar dysfunction; and 3) pyramidal tract disease or extrapyramidal disease. It has to be consistent with clinical description of CTE and clinically distinguishable from other disease processes. The possible CTE must be consistent with clinical description of CTE, but could be explained by other disease processes. The improbable CTE is inconsistent with clinical description of CTE and can be explained by other disease processes that are unrelated to brain trauma.

The differential diagnosis of CTE includes PCS and other neurodegenerative forms of dementia. Postconcussion syndrome has an acute onset and is temporally related to mild brain injury (concussion) without a latent period (35). If patients with PCS show signs of progression in neuropsychiatric symptoms several years after the last injury, they should be checked for the symptoms of CTE. The differential diagnosis of early CTE with respect to Alzheimer’s disease is difficult. Brain trauma in personal history is a risk factor for both diagnoses. Patients with early stages of CTE tend to present with chronic headache and dominant behavioural and psychiatric symptoms (e.g. depression, mood swings, substance abuse, disinhibition). Dementia with short term memory deficits and parkinsonism are typical for later stages of CTE. In younger patients with repeated brain trauma, the diagnosis of CTE should be favoured. AD is infrequent in this younger population (22). Both, the behavioural variant of frontotemporal lobar degeneration (bvFLD) and CTE affect younger patients and both are associated with motor neuron disease. Unlike CTE, bvFLD has a faster progression and different memory impairment characteristics (37). When comparing CTE to dementia with Lewy bodies (DLB), the combination of dementia and parkinsonism tend to occur early in DLB but not in CTE. Mood swings with aggression and explosive behaviour are typical for CTE, but not for DLB (37).

There is no treatment for CTE but unlike other forms of dementia, it is preventable. More should be done in protection of players by changing the rules of sports, medical guidelines and modernising the protective equipment.

References


Tab. 1. Clinical presentation of CTE (32).

<table>
<thead>
<tr>
<th>Symptom/Sign</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor features</td>
<td>Dysarthria, including scanning speech, Spasticity, Ataxia, including incoordination, Parkinsonism, including tremors, Gait disturbance, Motor neuron disease (possibly)</td>
</tr>
<tr>
<td>Cognitive features</td>
<td>Executive dysfunction, Impaired attention and concentration, Memory problems, Executive dysfunction, Dementia, Visuospatial difficulties, Language impairment</td>
</tr>
<tr>
<td>Behavioural and psychiatric features</td>
<td>Aggression and/or agitation, Apathy, Impulsivity, Depression, Delusions (such as paranoia), Suicidal behaviour</td>
</tr>
</tbody>
</table>

The literature to date lacks prospective epidemiological studies of the incidence of CTE (23).

CTE presents with behavioural, cognitive, and motor symptoms (Tab. 1). The typical onset is between 30 and 65 years of age (35). When compared to other neurodegenerative diseases such as Alzheimer’s disease and frontotemporal lobar degeneration, CTE progression tends to be slower (in tens of years) (36). The earliest findings in patients with CTE are mostly behavioural in form of mood changes including poor impulsivity control, aggression, explosive behaviour, risky behaviour leading to bankruptcy, substance abuse, apathy, and depression with high incidence of suicide. Among cognitive changes the early ones are impaired attention, executive dysfunction, and memory problems. Motor symptoms tend to occur in later stages of the disease (35).

Pathological findings in CTE differ from other neurodegenerative diseases/taupathies such as Alzheimer’s disease and frontotemporal lobar degeneration (37). Typical macroscopic pathological findings in patients with CTE are brain atrophy, enlargement of ventricles, cavum septum pellucidum and pallor of the locus coeruleus and substantia nigra. Typical microscopic findings are neurofibrillary tangles (95–100 % of patients), TDP-43 inclusions (86 %), neuritic amyloid β plaques (30–53 %) (30, 36). In the largest study of patients with CTE to date, McKee et al classify CTE progression in four stages (36). Pathological process with findings of neurofibrillary tangles with phosphorylated tau protein begins focally, perivascularly in sulcal depths of frontal cortices (Stage 1) and spreads during the years up to most regions of the cortex, medial temporal structures, brainstem, and spinal cord (Stage 4). Due to these pathological findings it is suggested that CTE belongs to the group of progressive taupathies (32, 36). We still do not know the exact pathophysiological mechanisms of tau protein hyperphosphorylation, oligomerization, and transfer from cell to cell. McKee et al have suggested that repeated head injuries and deposits of hyperphosphorylated tau protein lead to other protein deposits such as TDP-43, amyloid β and α-synuclein.

Clinical features of CTE include:

- Executive dysfunction, and memory problems.
- Motor symptoms (Tab. 1). The typical onset is between 30 and 65 years of age.

The most frequent clinical presentation of CTE is behavioural, cognitive, and motor symptoms (Tab. 1). The typical onset is between 30 and 65 years of age (35). When compared to other neurodegenerative diseases such as Alzheimer’s disease and frontotemporal lobar degeneration, CTE progression tends to be slower (in tens of years) (36). The earliest findings in patients with CTE are mostly behavioural in form of mood changes including poor impulsivity control, aggression, explosive behaviour, risky behaviour leading to bankruptcy, substance abuse, apathy, and depression with high incidence of suicide. Among cognitive changes the early ones are impaired attention, executive dysfunction, and memory problems. Motor symptoms tend to occur in later stages of the disease (35).

Pathological findings in CTE differ from other neurodegenerative diseases/taupathies such as Alzheimer’s disease and frontotemporal lobar degeneration (37). Typical macroscopic pathological findings in patients with CTE are brain atrophy, enlargement of ventricles, cavum septum pellucidum and pallor of the locus coeruleus and substantia nigra. Typical microscopic findings are neurofibrillary tangles (95–100 % of patients), TDP-43 inclusions (86 %), neuritic amyloid β plaques (30–53 %) (30, 36). In the largest study of patients with CTE to date, McKee et al classify CTE progression in four stages (36). Pathological process with findings of neurofibrillary tangles with phosphorylated tau protein begins focally, perivascularly in sulcal depths of frontal cortices (Stage 1) and spreads during the years up to most regions of the cortex, medial temporal structures, brainstem, and spinal cord (Stage 4). Due to these pathological findings it is suggested that CTE belongs to the group of progressive taupathies (32, 36). We still do not know the exact pathophysiological mechanisms of tau protein hyperphosphorylation, oligomerization, and transfer from cell to cell. McKee et al have suggested that repeated head injuries and deposits of hyperphosphorylated tau protein lead to other protein deposits such as TDP-43, amyloid β and α-synuclein.

Clinical features of CTE include:

- Executive dysfunction, and memory problems.
- Motor symptoms (Tab. 1). The typical onset is between 30 and 65 years of age.

The most frequent clinical presentation of CTE is behavioural, cognitive, and motor symptoms (Tab. 1). The typical onset is between 30 and 65 years of age (35). When compared to other neurodegenerative diseases such as Alzheimer’s disease and frontotemporal lobar degeneration, CTE progression tends to be slower (in tens of years) (36). The earliest findings in patients with CTE are mostly behavioural in form of mood changes including poor impulsivity control, aggression, explosive behaviour, risky behaviour leading to bankruptcy, substance abuse, apathy, and depression with high incidence of suicide. Among cognitive changes the early ones are impaired attention, executive dysfunction, and memory problems. Motor symptoms tend to occur in later stages of the disease (35).

Pathological findings in CTE differ from other neurodegenerative diseases/taupathies such as Alzheimer’s disease and frontotemporal lobar degeneration (37). Typical macroscopic pathological findings in patients with CTE are brain atrophy, enlargement of ventricles, cavum septum pellucidum and pallor of the locus coeruleus and substantia nigra. Typical microscopic findings are neurofibrillary tangles (95–100 % of patients), TDP-43 inclusions (86 %), neuritic amyloid β plaques (30–53 %) (30, 36). In the largest study of patients with CTE to date, McKee et al classify CTE progression in four stages (36). Pathological process with findings of neurofibrillary tangles with phosphorylated tau protein begins focally, perivascularly in sulcal depths of frontal cortices (Stage 1) and spreads during the years up to most regions of the cortex, medial temporal structures, brainstem, and spinal cord (Stage 4). Due to these pathological findings it is suggested that CTE belongs to the group of progressive taupathies (32, 36). We still do not know the exact pathophysiological mechanisms of tau protein hyperphosphorylation, oligomerization, and transfer from cell to cell. McKee et al have suggested that repeated head injuries and deposits of hyperphosphorylated tau protein lead to other protein deposits such as TDP-43, amyloid β and α-synuclein.


Received April 14, 2015. Accepted August 18, 2015.